Fortrea Increases Patient Access Capabilities and Cold Chain Expertise with FortreaRx™ Expansion

Fortrea’s non-commercial specialty pharmacy expansion delivers flexible, scalable solutions to customers and life-changing medications direct to patients DURHAM, N.C., Feb. 20, 2024 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced the opening of its expanded non-commercial specialty pharmacy, FortreaRx™, located in Lake Mary, Florida, which offers […]

Fortrea’s non-commercial specialty pharmacy expansion delivers flexible, scalable solutions to customers and life-changing medications direct to patients

DURHAM, N.C., Feb. 20, 2024 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced the opening of its expanded non-commercial specialty pharmacy, FortreaRx™, located in Lake Mary, Florida, which offers advanced patient access solutions across the United States, including ambient and cold-chain distribution capabilities and expertise.

Licensed in all 50 states and U.S. territories, FortreaRx delivers flexible, scalable solutions that meet the specific needs of its customers while providing medications to patients who may otherwise not have access to them. Non-commercial specialty pharmacies, like FortreaRx, provide these solutions on behalf of their pharmaceutical manufacturer customers and are uniquely positioned to serve as a bridge between pharmaceutical manufacturers and patients who meet the manufacturer requirements for prescription assistance.

Since FortreaRx’s inception in late 2008, Fortrea has pioneered non-commercial specialty pharmacy services, focusing exclusively on the distribution of free-goods products as an integrated component of pharmaceutical manufacturer-sponsored patient assistance programs (PAP) designed to expand access to therapy for qualified patients with no health insurance or those who are underinsured. The FortreaRx 40,000-square-foot facility doubles its operational space and bolsters its capabilities, delivering:

  • 1,800 square feet of ambient storage
  • 6,000+ square feet of cold chain storage with more than 85 percent of prescriptions filled by FortreaRx requiring this unique handling
  • Greater processing and fulfillment space for up to 18,000 prescriptions daily
  • Enhanced shipping solutions with options for overnight, expedited and 2-day deliveries

“Fortrea’s well-established patient services offerings, combined with the expanded capabilities of FortreaRx, deliver an end-to-end approach, from early clinical stages to post-market delivery, ensuring a comprehensive and personalized experience for patients,” said Bill Nolan, vice president and global head of Patient Access at Fortrea. “From our expertise in broad-range disease states to our unwavering commitment to patient assistance, Fortrea excels at delivering timely and impactful solutions to our pharmaceutical sponsors that strive to reduce patient and provider challenges by streamlining enrollment processes and by offering full integration with broader patient support initiatives.”

FortreaRx’s call center hub of case managers seamlessly manages patient inquiries, counseling and data verification of prescriptions. Fortrea’s patient access team helps patients and providers understand and navigate the complexities of coverage while removing obstacles to get medication to patients.

FortreaRx delivers efficient, consultative and cost-effective solutions for manufacturer prescription programs typically resulting in significant yearly savings for patients.

For more information about FortreaRx and its services, please visit Fortrea.com.

About Fortrea

Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients in need. Fortrea provides phase I-IV clinical trial management, clinical pharmacology, differentiated technology-enabled trial solutions and post-approval services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team of about 19,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter) @Fortrea.

Fortrea Contacts:
Fortrea Media: Galen Wilson – 703-298-0802, media@fortrea.com
Fortrea Media: Kate Dillon – 646-818-9115, kdillon@prosek.com

GlobeNewswire Distribution ID 9040223

Total
0
Shares
Previous Article

Axi Select hailed as the future of prop trading as multiple demo account firms close doors due to pressures from regulators, brokers, and tech providers

Next Article

OnePlus Launches the New Nord N30 SE 5G – Bigger, Louder, Faster

Related Posts

Canton Fair: Exhibitors’ Creative Livestreams Appeal to Buyers

GUANGZHOU, China, April 23, 2022 /PRNewswire/ — The 131st Canton Fair, which takes place online from 15 to 24 April, attracts over 25,000 exhibitors from home and abroad. Given the virtual form of the event, making better use of the cloud platform to boost cooperation and identify business opportunities comes as an important matter for exhibitors […]

ROSEN, A LONGSTANDING LAW FIRM, Encourages Alphabet Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GOOG, GOOGL

NEW YORK, March 24, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Alphabet Inc. (NASDAQ: GOOG, GOOGL), the parent company of Google, between February 4, 2020 and January 23, 2023, both dates inclusive (the “Class Period”). […]

‫”دار الأركان” تتعاون مع “باجاني أوتوموبيلي” لتشييد البرج السكني الحصري الفاخر “دافينشي” في إمارة دبي

DUBAI, UAE, 16 ديسمبر / كانون أول 2021 /PRNewswire/ — أعلنت “دار الأركان”، شركة التطوير العقاري الرائدة في المملكة العربية السعودية ودول مجلس التعاون الخليجي، عن إطلاق مشروع البرج السكني “دافينشي” في دبي بالشراكة مع “باجاني أوتوموبيلي”، الشركة الإيطالية المتخصصة في تصنيع السيارات الرياضية، والتي تشتهر بإنتاج سيارات حصرية ومصنوعة يدوياً بإصدارات محدودة للغاية. ويتوج إطلاق […]